|
| 36849448 | Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older. | | 2023 |
| 36757131 | Impact of preventive pill-based treatment on migraine days: A secondary outcome study of the Childhood and Adolescent Migraine Prevention (CHAMP) trial and a comparison of self-report to nosology-derived assessments. | | 2023 |
| 37326643 | Predicting chronic postsurgical pain: current evidence and a novel program to develop predictive biomarker signatures. | Pain | 2023 |
| 35164870 | Antemortem detection of Parkinson's disease pathology in peripheral biopsies using artificial intelligence. | Acta neuropathologica communications | 2022 |
| 35970588 | Statistical Considerations in the Design of Clinical Trials Targeting Prodromal Parkinson Disease. | Neurology | 2022 |
| 35995594 | Association of Olfactory Performance With Motor Decline and Age at Onset in People With Parkinson Disease and the G2019S Variant. | Neurology | 2022 |
| 35547202 | Multi-Site Observational Study to Assess Biomarkers for Susceptibility or Resilience to Chronic Pain: The Acute to Chronic Pain Signatures (A2CPS) Study Protocol. | Front Med (Lausanne) | 2022 |
| 34744052 | Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson's Disease. | J Parkinsons Dis | 2022 |
| 34865085 | Multimodal Assessment of Medication Adherence Among Youth With Migraine: An Ancillary Study of the CHAMP Trial. | Journal of Pediatric Psychology | 2022 |
| 34404270 | Trajectory of treatment response in the child and adolescent migraine prevention (CHAMP) study: A randomized clinical trial. | Cephalalgia | 2022 |
| 34857535 | Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study. | Neurology | 2022 |
| 35088051 | Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. | Neurooncol Adv | 2021 |
| 37265855 | A cluster randomized trial to evaluate a centralized remote clinical pharmacy service in large, health system primary care clinics. | J Am Coll Clin Pharm | 2021 |
| 33635141 | Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis. | Multiple Sclerosis Journal | 2021 |
| 33460301 | Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype. | Annals of Clinical and Translational Neurology | 2021 |
| 33942926 | Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease. | Mov Disord | 2021 |
| 34257421 | Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study. | Genet Med | 2021 |
| 34251445 | Prevalence of Headache Days and Disability 3 Years After Participation in the Childhood and Adolescent Migraine Prevention Medication Trial. | JAMA network open | 2021 |
| 33315105 | Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. | JAMA Neurol | 2021 |
| 33054533 | Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis. | Multiple Sclerosis Journal | 2021 |
| 33321002 | Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder. | Ann Clin Transl Neurol | 2021 |
| 34742348 | High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease. | Acta Neuropathol Commun | 2021 |
| 34656902 | Low soluble amyloid-β 42 is associated with smaller brain volume in Parkinson's disease. | Parkinsonism and Related Disorders | 2021 |
| 32798333 | Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. | Mov Disord | 2020 |
| 32202612 | Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials. | JAMA Neurol | 2020 |
| 31914647 | Improving natural product research translation: From source to clinical trial. | FASEB J | 2020 |
| 32073681 | Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study. | Mov Disord | 2020 |
| 32102975 | Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? | Neurology | 2020 |
| 32285645 | Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. | Ann Clin Transl Neurol | 2020 |
| 32542885 | Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. | Ann Neurol | 2020 |
| 33207828 | Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial. | J Clin Med | 2020 |
| 32747521 | In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease. | Neurology | 2020 |
| 31361367 | Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease. | Mov Disord | 2019 |
| 30554993 | Self-reported physical activity levels and clinical progression in early Parkinson's disease. | Parkinsonism Relat Disord | 2019 |
| 30450637 | Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. | Ann Neurol | 2019 |
| 31526747 | Antisense oligonucleotides might change the therapeutic landscape for Huntington's disease. | Lancet Neurology, The | 2019 |
| 31450510 | Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures. | J Parkinsons Dis | 2019 |
| 31125734 | Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson's disease. | Journal of the Neurological Sciences | 2019 |
| 29331037 | Pharmacist Intervention for Blood Pressure Control in Patients with Diabetes and/or Chronic Kidney Disease. | Pharmacotherapy | 2018 |
| 28986467 | Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort. | J Neurol Neurosurg Psychiatry | 2018 |
| 30223401 | Motor Function Test Reliability During the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study. | Journal of Neuromuscular Diseases | 2018 |
| 30157388 | Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. | N Engl J Med | 2018 |
| 30107604 | Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4). | J Neuropathol Exp Neurol | 2018 |
| 30248065 | Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4). | J Parkinsons Dis | 2018 |
| 30094386 | Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA! | Contemp Clin Trials Commun | 2018 |
| 30125297 | Cognition among individuals along a spectrum of increased risk for Parkinson's disease. | PLoS One | 2018 |
| 29572948 | Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. | Mov Disord | 2018 |
| 28128463 | The Childhood and Adolescent Migraine Prevention (CHAMP) Study: "What Do We Do Now?" | Headache | 2017 |
| 28734051 | A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations. | Movement Disorders | 2017 |
| 28554959 | Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease. | J Neurol Neurosurg Psychiatry | 2017 |